Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis.
Taihei SuzukiMasahide MizobuchiShunsuke YoshidaNarumi TeradoShugo AokiNozomi SatoHirokazu HondaPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)
Osteoporosis is a crucial complication in patients with chronic kidney disease (CKD), similar to that in the general population. Although romosozumab, a monoclonal antibody targeting sclerostin, has been administered for patients with CKD, its clinical effectiveness in these patients, especially in patients on hemodialysis (HD), remains to be studied. Herein, we report the case of a 42-year-old man on HD who developed severe osteoporosis. Serum calcium levels were extremely high, bone metabolic markers were abnormal, and the patient had pathological fractures. The bone biopsy indicated a bone metabolism disorder and high bone turnover. We administered romosozumab once a month as an intervention for bone alteration. Through the 10-month usage, bone metabolic markers improved, and the decrease in bone mineral density was ameliorated. We hypothesized that romosozumab could be a therapeutic option for osteoporosis in patients undergoing HD, especially in those with bone mineralization disorders.
Keyphrases
- bone mineral density
- postmenopausal women
- end stage renal disease
- body composition
- chronic kidney disease
- peritoneal dialysis
- patients undergoing
- ejection fraction
- randomized controlled trial
- monoclonal antibody
- newly diagnosed
- prognostic factors
- systematic review
- polycystic kidney disease
- early onset
- bone regeneration
- patient reported outcomes